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The SARS-CoV-2 virus is the causative agent of the global COVID-19 infectious disease outbreak, which can lead
to acute respiratory distress syndrome (ARDS). However, it is still unclear how the virus interferes with immune
cell and metabolic functions in the human body. In this study, we investigated the immune response in acute or
convalescent COVID-19 patients. We characterized the peripheral blood mononuclear cells (PBMCs) using flow
cytometry and found that CD8þ T cells were significantly subsided in moderate COVID-19 and convalescent
patients. Furthermore, characterization of CD8þ T cells suggested that convalescent patients have significantly
diminished expression of both perforin and granzyme A. Using 1H-NMR spectroscopy, we characterized the
metabolic status of their autologous PBMCs. We found that fructose, lactate and taurine levels were elevated in
infected (mild and moderate) patients compared with control and convalescent patients. Glucose, glutamate,
formate and acetate levels were attenuated in COVID-19 (mild and moderate) patients. In summary, our report
suggests that SARS-CoV-2 infection leads to disrupted CD8þ T cytotoxic functions and changes the overall
metabolic functions of immune cells.1. Introduction
The first cases of severe acute respiratory coronavirus-2 (SARS-CoV-
2) infection appeared in December 2019, in Wuhan, China [1]. This
zoonotic virus has infected by now more than 127.8 million people
(30.03.2021) and has resulted in more than 2.78 million death world-
wide [2, 3]. The containment of the pandemic is challenging and is still
growing with roughly 200,000 or more new infections being reported
daily since July 2020 [2,3]. There is an urgent need for a better under-
standing of the immunopathology, as SARS-CoV-2 has become the
leading cause of morbidity (long COVID syndrome) and mortality in
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Y. Singh et al. Heliyon 7 (2021) e07147people develop mild to moderate illness and recover without hospitali-
zation [12, 13]. High serum levels of IL-6, IL-8, IL-10, TNF-α cytokines
and an immune hyper-responsiveness referred to as a 'cytokine storm' is
connected with poor clinical outcome [14, 15]. Predominantly, older
COVID-19 patients can develop acute severe respiratory distress syn-
drome (ARDS) due to a cytokine storm which is a life-threatening situ-
ation, requiring ventilation and intensive care support [16, 17, 18, 19,
20].
Several breakthrough discoveries have extended our understanding
as to how the virus takes advantage of the host and modulates immunity
[12, 19, 21, 22, 23, 24, 25]. Recovered COVID-19 patients have an
increased number of antibody-secreting cells and activated CD4þ and
CD8þ T cells. Further, Immunoglobulin M (IgM) and SARS-CoV-2 reac-
tive IgG antibodies were also detected in blood before full symptomatic
recovery [26, 27, 28]. Most severely affected COVID-19 patients had a
lower T cell but elevated B cell counts when compared with healthy
controls [13, 14, 29, 30]. Interestingly, patients with mild symptoms
were also shown to have increased T and B cells compared with severely
affected patients [26, 29, 30, 31]. There could be several reasons for
different disease outcomes including an over-activated innate or
hyper-activated adaptive immune response leading to cytokine storms
and resulting in severe injury to the lungs [10, 13, 25, 32]. Despite
several ongoing efforts, the immunological mechanisms of the
host-pathogen interaction are not well understood [33].
There is an intricate balance between the metabolic state of immune
cells and the generation of a robust immune response [19, 34, 35, 36,
37]. CD8þ T cells require energy to proliferate and accomplish their
effective functions [38]. Most propagating cells such as lymphocytes
utilize the most abundant energy substrates including, glucose, lipids and
amino acids [39]. In response to SARS-CoV-2 and other virus infections,
CD8þ T cells play a pivotal role. They undergo profound growth and
proliferation to generate their effective functional cells which can pro-
duce copious amounts of effector molecules such as cytokines and cyto-
toxic granules [30, 38, 39, 40]. An activated immune system is coupled
with a change in metabolic reprogramming to produce enough energy
needed during (viral) infection [38, 39]. Proliferating T cells ferment
glucose to lactate even in the presence of oxygen to meet high energy
demands [34, 37, 38, 39]. Furthermore, glucose and glutamine are
involved in the hexosamine biosynthetic pathway, which regulates the
production of uridine diphosphate N-acetyl glucosamine necessary for T
cell clonal expansion and function [41]. The synthesis of lactate intra-
cellularly is crucial for T cells to have an increased glycolytic flux [38].
Peripheral blood mononuclear cells (PBMCs) can be analyzed to
measure the physiological dysfunctionality of an individual and can serve
as a biomarker [42]. Consequently, the metabolic status of lymphocytes
could help to predict disease severity or to select the optimal therapeuticTable 1. Patient demographics.
No COVID-19 status Blood sampling
1 Outpatient (mild) Day 1
2 Outpatient (mild) Day 1
3 Outpatient (mild) Day 1
4 Inpatient (moderate) Day 7
5 Inpatient (moderate) Day 7
6 Inpatient (moderate) Day 7
7 Convalescent (Sero þve) Convalescent
8 Convalescent (Sero þve) Convalescent
9 Convalescent (Sero þve) Convalescent







intervention to boost the immune function during infection. Generally,
most of the metabolism-related functions in PBMCs during SARS-CoV-2
infections were inferred based on transcriptomics analysis [34, 43] and
no functional data (biochemical level) have been presented. Therefore,
understanding the kinetics of the adaptive immune response as well as
the metabolic functions during SARS-CoV-2 infection will help to eluci-
date the host immune response to SARS-CoV-2 infection. In this study,
using flow cytometry and proton nuclear magnetic resonance (1H-NMR)
spectroscopy, we characterized the PBMCs from SARS-CoV-2 infected
and convalescent patients for their immunophenotypic and metabolic
functions.
2. Results
2.1. Characteristics of study participants
PBMCs were isolated and cryopreserved from blood samples obtained
from COVID-19 patients suffering from mild (‘Mild (outpatient)’) or
moderate/severe (‘Moderate (inpatient)’) disease or were already
recovered (‘Convalescent’) and from healthy controls (‘HC’). Classifica-
tion of disease severity for this analysis was based on the requirement of
hospitalization. Patients with mild COVID-19were recruited within three
days after confirmation of infection by RT-qPCR. From moderate to se-
vere COVID-19 patient blood samples were collected one week after their
hospital admittance. Themoderate patients were admitted to the hospital
requiring medical care; however, they did not need ventilation or O2
supply. Recovered patients were included based on a positive SARS-CoV-
2 antibody testing. Study participant characteristics are described in
Table 1.
2.2. Immunophenotyping of COVID-19 mild, moderate and convalescent
COVID-19 patients
To compare the number of lymphocytes and monocytes amongst the
four study groups, PBMCs were stained and analysed by flow cytometry.
Based on live-cell percentage count (gating strategy; Figure 1a), both,
lymphocytes and monocytes were not significantly different among mild,
moderate and convalescent COVID-19 patients compared with HC
(Figure 1b-d).
2.3. Increased inflammatory monocytes and reduced NK cells in moderate
COVID-19 patients
Monocytes were further classified into classical, non-classical and
intermediate based on the expression of CD16 and/or CD14 and were
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Figure 1. Total % counts of monocytes and lymphocytes from PBMCs of COVID-19 patients. a. Fixed PBMCs samples (1  106 cells) were collected and subsequently
acquired on flow cytometry. A total of 200,000 cells were acquired by flow cytometry and gating was performed based on FSC and SSC parameters for lymphocytes,
monocytes and dead cells as described earlier [76, 77, 78]. Gating strategy for T lymphocytes (CD3, CD4 and CD8) monocytes (CD14 and CD16) [44], NK cells (CD56)
using FMO controls. b. The bar graphs represent the % of lymphocytes and monocytes. c–d. The representative gated lymphocytes and monocytes FACS plots. The bar
graphs represent the % of lymphocytes and monocytes.
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Figure 2. Comparison of monocytes and NK cell percentage amongst study groups. a. The stained PBMCs were gated on the monocyte population and CD3þCD19þ
cells were excluded. Cell populations are displayed for CD16 and CD14 expression (upper FACS panel). One exemplary dot plot is shown per study group. The bar
diagrams (lower panel) show the non-classical (CD16þCD14-), intermediate (CD16þCD14þ) and classical (CD16CD14þ) monocytes. *P-value 0.05, **P-value 0.01
and ***P-value 0.001. b. UMAP plot for different subsets of monocytes (non-classical, intermediate and classical monocytes; left UMAP plot) from all the samples.
Group comparisons among HC, mild and moderate (right UMAP plot). Colour-coded information is provided for either different subsets of monocyte populations or
patient groups. c. The stained PBMCs were gated on lymphocyte population and further excluded the CD3þCD19þ cells and examined for the CD56 and CD8
expression in HC, mild, moderate and convalescent (upper FACS panel). One exemplary dot plot is shown per study group. The bar diagram shows the
CD56þCD8þCD3CD19- NK cells. *P-value 0.05.
Y. Singh et al. Heliyon 7 (2021) e07147patrolling (non-classical) monocytes were significantly increased (p ¼
0.0004) in percentage in moderate patients compared to HC, whereas
this number is decreased again significantly compared with convales-
cent patients (p ¼ 0.001) (Figure 2a). The percentage of CD16þCD14-
(non-classical) monocytes was also significantly increased (p ¼ 0.006)
in moderate patients compared with mild patients (Figure 2a Panel I;
left). Interestingly, CD16þCD14þ pro-inflammatory monocytes (inter-
mediate) were again significantly increased in mild (p ¼ 0.03) and
moderate (p ¼ 0.002) compared with HC as well as between moderate
and convalescent (p ¼ 0.005) (Figure 2a panel II; middle). Furthermore,
we observed a significantly reduced percentage of CD14þCD16-
phagocytic monocytes (classical) in moderate compared with mild (p ¼
0.004), HC (p < 0.0002) and convalescent (p ¼ 0.0007) patients
(Figure 2a Panel III; right). Based on the results above using classical 2D
flow cytometry analysis, we observed a major difference between HC vs
mild or with moderate COVID-19 patient samples, therefore, we5
concatenated three groups together (equal number of cells from each
sample; HC, mild and moderate) to identify the visual clustering of
monocytes using Uniform Manifold Approximation and Projection
(UMAP) for dimension reduction algorithm [45] (Figure 3). Based on
UMAP dimension reduction analysis (data-driven and gated cells), we
observed a clear difference in the different subsets of monocytes be-
tween all three groups (Figures 3c, d and 2b). We observed that mod-
erate COVID-19 patients mostly cluster in non-classical and partially in
intermediate monocyte regions compared to HC, whilst mild COVID-19
patients cluster in all non-classical, intermediate and classical mono-
cytes regions (Figure 2b; right). We then explored the lymphoid cells
compartment for NK cells (CD56þCD8þCD3CD19-). We found that
moderate patients were significantly different from HC (p ¼ 0.04).
There was also a tendency of a decrease in NK cells in mild patients
compared with HC (p ¼ 0.07), although, not reaching statistical sig-
nificance (Figure 2c).Figure 3. UMAP analysis of lymphocytes and mono-
cytes cell populations. a. UMAP pseudo-colour plot
was derived from all the samples. All the FCS files
(used only live cell gated population; minimum cells
per samples were 25,000) were concatenated from HC,
mild and moderate patients (upper panel). Represen-
tation of lymphocytes and monocytes populations in
UMAP plot (middle panel). Presentation of different
lymphocytes subpopulations like CD4þ T cells, CD8þ T
cells, B cells, NK cells, NKT cells and regulatory T cells
(lower panel). b. UMAP plot for overlaying of different
groups. c. UMAP plot for different subsets of mono-
cytes. d. UMAP plots for individual antibody (protein)
expression on monocyte populations. Scale bar shows
the expression level of protein expression on the cell
clusters (blue -lowest and red highest expression;
relative expression).
Figure 4. Increased B cells in mild and moderate patients and reduced CD8þ cytotoxic T cells in moderate and convalescent patients. a. The stained PBMCs were gated
on lymphocyte population and examined for the CD19 and CD3 expression in HC, mild, moderate and convalescent (upper FACS panel). One exemplary dot plot is
shown per study group. The bar diagram shows CD3CD19þ B cells. *P-value 0.05, **P-value 0.01 and ***P-value 0.001. b. The CD19CD3þ lymphocytes were
examined for CD4þ and CD8þ T marker expression. One exemplary dot plot is shown per study group. There was statistically significant difference among HC,
moderate and convalescent (upper FACS panel). CD8þ T cells were significantly reduced in moderate and convalescent groups. *P-value 0.05.
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Figure 5. Kinetics of regulatory T cells is not affected significantly in mild, moderate and convalescent patients. Foxp3þ expression on CD19CD3þCD4þCD45RA T
cells to identify the regulatory T cells in HC, inpatient, outpatient and convalescent (upper FACS panel).
Y. Singh et al. Heliyon 7 (2021) e071472.4. Dynamics of B and T cells in mild, moderate and convalescent patients
Both T and B cells are indispensable for the immune response against
viral infections including SARS-CoV-2. Firstly, we compared the number
of B cells, which give rise to virus-specific antibodies (see the gating
strategy in Figure 1a). The CD19þCD3- cells (B cells) were significantly
increased in mild (p ¼ 0.008; fold change x1.7) and moderate (p ¼
0.0008; fold change x1.9) patients compared with HC (Figure 4a). B cells
were significantly decreased in moderate patients compared to conva-
lescent (p ¼ 0.04) group (Figure 4a). Comparing CD3þCD19- lympho-
cytes among the different patient groups we observed no significant
difference. Moreover, CD3þ cells were analysed for the CD4þ and CD8þ T
cell compartment. There was a tendency of increased CD4þ T cells for
mild, moderate, and convalescent patients compared to HC, but no sig-
nificant difference was observed among any of the groups. CD8þ T cells
were significantly different between HC compared to moderate (p ¼
0.04) patients or convalescent (p ¼ 0.04) group (Figure 4b). Finally, we
characterized CD4þFOXP3þCD45R regulatory T cells (Tregs), however,
no significant difference was observed among the different groups
(Figure 5).
2.5. Impaired activation and defective cytotoxic functions of CD8þ T cells
We found that the percentage of CD8þ T cells was decreased in
moderate and convalescent patients compared to HC. Thus, we explored
the activation status of CD8þ T cells based on HLA-DR expression. We
found that CD8þ T cell activation status (HLA-DR expression) in all three
groups of infected patients was significantly different from HC (mild p ¼
0.01, moderate p ¼ 0.01, and convalescent p ¼ 0.01, Figure 6a). We
characterized the cytotoxic potential of CD8þ T cells based on granzyme
A and perforin levels and found that there was a tendency of decreased7
granzyme A expression in mild and moderate patients compared with HC
(Figure 6b), however, it did not reach statistical significance. Granzyme
Aþ/perforinþ expression was significantly decreased in convalescent (p
¼ 0.02) group comparedwith HC (Figure 6b), althoughmild patients also
had reduced levels (p ¼ 0.07), it did not reach statistical significance.
Furthermore, we studied the expression of CD38, a marker of immune
cell activation, which was significantly upregulated in convalescent pa-
tients group compared with HC (p ¼ 0.04) (Figure 7a). Similarly,
convalescent patients group had significantly increased numbers of PD-
1þ CD38þ cytotoxic CD8þ T cells compared with HC (p ¼ 0.006), mod-
erate (p¼ 0.005) andmild (p¼ 0.002), which reflects the exhaustion and
non-responsiveness (anergy) of CD8þ T cells (Figure 7b). Overall, our
data suggested that CD8þ T cells have reduced activation, diminished
expression of cytotoxic molecules such as perforin and granzyme A and
have a severely exhausted phenotype.
2.6. Dynamics of metabolites production in the mild, moderate and
convalescent patient
To establish a putative link between the metabolic state of immune
cells and the impaired immune response, PBMCs from all patient groups
were subjected to 1H-NMR spectroscopy analysis. We identified and
quantified a total of 18 metabolites (Figure 8a). Hereby, unsupervised
Principal Component Analysis (PCA) showed that spectral data frommild
and moderate patients formed overlapping clusters. However, HC and
convalescent patients clustered together (Figure 8b), indicating a strong
difference in metabolite levels between an infectious state compared to
healthy or recovered groups. Statistical analysis of the four different
groups revealed that 15 metabolites showed p-values < 0.05, with the
highest significance for metabolites related to energy metabolism
(Figures 8c and 9 & Table 2). The data indicate that during infection,
Figure 6. Decreased activation and cytotoxic functional protein expression of CD8þ T cells in convalescent patients group. a. CD8þ T cells were examined for the
expression of activation marker HLA-DR (upper FACS panel). One exemplary dot plot is shown per study group. The bar diagram (lower panel) shows that HLA-DR was
a significantly lower on CD8þ T cells in mild, moderate and convalescent COVID-19þ patients compared with HC. *P-value 0.05. b. CD8þ T cells were examined for
the expression of their cytotoxic potential using granzyme A and perforin expression using IC staining (upper FACS panel). One exemplary dot plot is shown per study
group. The bar diagram (lower panel; right-hand side) shows that perforinþ/granzyme Aþ expression was significantly lower on CD8þ T cells in convalescent group
compared with HC, though mild and moderate represent a lower expression of perforin, but it did not reach to a significant level. *P-value 0.05.
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etate and formate, whilst lactate levels are increased. Furthermore, we
also found very high levels of fructose in PBMCs from mild patients,
medium concentrations in moderate and, low levels in HC and conva-
lescent patients (Figure 8c). Furthermore, glutamate was almost abol-
ished in mild and moderate patients, potentially as a consequence of
enhanced production of α-ketoglutarate in the TCA cycle in PBMCs via
glutamate dehydrogenase (Figure 8c). Levels of other amino acids such as
glycine and isoleucine were low in mild and moderate patients compared
with HC, while creatine and alanine were high in mild patient and
moderate patient respectively (Figure 8c).
To find an association between different metabolites, we applied the
variable importance of projection (VIP) score. We found that formate and
glucose had the highest score compared to other metabolites
(Figure 10a). To determine if additional metabolites are positively
associated with changes in glucose, lactate and fructose, we performed a
pattern hunter analysis for all metabolites. We found that high glucose
levels correlated with high formate, acetate and glutamate and low
lactate and fructose (Figure 10b), indicating enhanced glycolysis and
TCA cycle activity in PBMCs. Similarly, fructose, which enters via
fructose-1-phosphate and dihydroxyacetone phosphate (DAP) into the
glycolysis pathway, is correlated positively with lactate and citrate and a
decrease in acetate and formate, respectively (Figure 10b). Interestingly,
levels of the ROS scavenger taurine are only positively correlated with
lactate and fructose, but not glucose (Figure 10c, d).
3. Discussion
SARS-CoV-2 infections are an intense and rapidly evolving area of
research due to the ongoing global pandemic [14, 25]. In this study, we
used flow cytometry and 1H-NMR to decipher the cell proportions and
functional state of immune cells (PBMCs) in mild, moderate and conva-
lescent COVID-19 patients compared to HC. Recent reports from
COVID-19 patients suggested that mild and severe patient had lympho-
penia [11, 46, 47, 48]. Here, we found that the myeloid cell compartment
in PBMCs based on CD16 and CD14 markers suggested that the per-
centage of non-classical and intermediate monocytes were increased
during an active mild or moderate SARS-CoV-2 infection, once infections
are cleared the monocyte percentage numbers return to normal. These
results are in accordance with some of the recently published studies [49,
50, 51].
In our cohort, specifically CD56þCD8þNK cells were decreased dur-
ing active SARS-CoV-2 viral infections (moderate), while during recovery
the numbers were comparable to HC as reported by others [52]. Simi-
larly, another recent study supports our finding by showing the decrease
in the number of NK cell subsets in COVID-19 patients, with no change in
CD56bright or CD56dim cells [53]. Furthermore, based on single-cell















recovered COVID-19 patients [48]. Thus, altogether, it appears that
CD56þNK cells and their subsets could have an important function dur-
ing the ongoing and clearance of SARS-CoV-2 infections. However,
further validation studies are warranted using different in vivo model
systems with appropriate control groups to pinpoint the exact role of
different NK cell subsets in SARS-CoV-2 infection. CD19þ B lymphocytes
were increased during infection and remain slightly higher than HC, thus
reflecting the antibody response against the SARS-CoV-2 virus. Thus, our
data suggest that these patients were able to generate SARS-CoV-2 spe-
cific B cells, this needs further scientific validation.
A major difference was found in the T lymphocytes compartment.
CD8þ T cells were significantly decreased in moderate and convalescent
patients as reported earlier [52]. Thus, it appears that during viral
infection non-virus specific CD8þ T cells undergo apoptosis, whilst the
viral-specific surviving CD8þ T cells are clonally expanded but appeared
to have lost their effector functions [54]. To confirm this, we first
measured the activation status of CD8þ T cells and found that CD8þ T
cells appeared to be less activated based on their HLA-DR activation
marker [26]. Further, CD8þ T cells were examined for additional acti-
vation marker CD38, which is involved in cell adhesion, signal trans-
duction and calcium signalling [55], was found to be upregulated in
convalescent patients but not during active infection. These CD38þCD8þ
T cells also expressed higher levels of PD-1, which is an immune check-
point and marker of exhaustion [24, 30, 56, 57, 58]. PD-1 further guards
against autoimmunity, stimulates apoptosis of antigen-specific T cells
and promotes self-tolerance by suppressing T cell inflammatory activity
[59]. Thus, viral infection leaves convalescent patients with exhausted
phenotypes. We uncovered that there was not a significant change in the
numbers of Tregs in COVID-19 patients, although, there was a trend to-
wards elevated levels of Tregs in COVID-19 patients and reduced Tregs in
convalescent patients, in agreement with the previous studies [56].
A key finding of our study was the surprising observation that gran-
zyme A and perforin secreting CD8þ T cells were significantly reduced in
convalescent patients. These results are in agreement with the recent
single-cell transcriptomics analysis which suggests that granzyme B and
perforin-1 transcripts were also decreased in convalescent COVID-19
patients compared with moderate or severe illness [60]. In contrast to
our results, in young patients, granzyme A or B and perforin levels were
increased in mild and moderate cases. Conversely, in elderly COVID-19
patients, there was a reduced expression of granzyme A and perforin
[61]. Another study suggested that decreased perforin and granzyme A
levels in CD4þ T cells, CD8þ T cell and NK cells is associated with
severely afflicted COVID-19 patients [62]. Furthermore, single-cell
transcriptomics analysis of SARS-CoV-2 reactive CD8þ T cells in
exhausted and non-exhausted subsets were analyzed [63]. These
exhausted CD8þ T cells were increased in frequency and displayed lesser
cytotoxicity and inflammation features in mild COVID-19 patients













Figure 7. Increased exhausted CD8þ T cells in convalescent patients group. a. Expression of activation marker CD38 on CD8þ T cells (upper FACS panel). One
exemplary dot plot is shown per study group. The bar diagram (lower panel) shows that CD38 expression was significantly higher on CD8þ T cells in convalescent
COVID-19þ patients compared with HC. *P-value 0.05. b. Expression of activation marker CD38 and PD-1 on CD8þ T cells (upper FACS panel). One exemplary dot
plot is shown per study group. The bar diagram (lower panel) shows that PD-1þCD38þ expression was significantly higher on CD8þ T cells in convalescent group
compared with HC. **P-value 0.01.
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Figure 8. 1H-NMR spectroscopy of PBMC extracts. a. Heatmap of featured metabolites' concentrations plotted with SARS-CoV-2 progression group clustering. b.
Principle component analysis (PCA) was performed to identify the clustering of two different groups. HC and convalescent COVID-19 patient samples cluster together
while SARS-CoV-2 infected mild and moderate patients cluster in a separate cluster with PC1: 90.7% and PC2: 2.6%. c. Box plots for differentially abundantly present
metabolites in the different group including HC, mild, moderate, and convalescent COVID-19 patient groups. *P-value 0.05, **P-value 0.01 and ***P-value 0.001.
Y. Singh et al. Heliyon 7 (2021) e07147
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Figure 9. Metabolite analysis in COVID-19 patients. a. Analysis of Variance (ANOVA) for multi-group comparisons. b. Partial Least Squares Discriminant Analysis
(PLS-DA) scores plot. c. Hierarchical clustering of metabolites (distance measured with Pearson r correlation coefficient). d. Boxplots for branched-chain amino acids
valine and leucine.
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Table 3. Antibodies and other reagents used for Flow cytometry.
No. Product Name Clone Fluorochrome Product ID Company
NK cells and Monocytes (Panel 1)
1 CD3 UCHT1 eFluor 450 48-0038-42 Thermofisher
2 CD4 SK3 SuperBright 600 63-0047-42 Thermofisher
3 CD8a SK1 PerCP-eFluor 710 46-0087-42 Thermofisher
4 CD19 HIB19 eFluor 506 69-0199-42 Thermofisher
5 CD45-RA HI100 PE-Cy7 25-0458-42 Thermofisher
6 HLA-DR L243 Alexa Fluor 647 A51010 Thermofisher
7 CD38 HIT2 PE-eFluor 610 61-0389-42 Thermofisher
8 CD56 MEM188 PE MA119638 Thermofisher
9 CD16 3G8 Super Bright 702 67-0166-42 Thermofisher
10 CD14 61D3 Alexa Fluor 700 56-0149-42 Thermofisher
11 Foxp3 (IC) PCH101 FITC 11-4776-42 Thermofisher
CD8 exhaustion, T helper follicular cells (Tfh) and antibody-secreting cell (ASC) (Panel 2)
1 CD3 UCHT1 eFluor 450 48-0038-42 Thermofisher
2 CD19 HIB19 eFluor 506 69-0199-42 Thermofisher
3 CD4 SK3 Super Bright 600 63-0047-42 Thermofisher
4 CD8a SK1 PerCP-eFluor 710 46-0087-42 Thermofisher
5 CD38 HIT2 PE-eFluor 610 61-0389-42 Thermofisher
6 CD27 O323 Alexa Fluor 700 56-0279-42 Thermofisher
7 CXCR5 (CD185) MU5UBEE FITC 11-9185-42 Thermofisher
8 ICOS (CD278) C398.4A PE 12-9949-81 Thermofisher
9 PD-1 (CD279) eBioJ105 (J105) PE-Cy7 25-2799-42 Thermofisher
10 HLA-DR L243 Alexa Fluor 647 A51010 Thermofisher
Cytotoxic potential
1 CD4 SK3 SuperBright 600 63-0047-42 Thermofisher
2 CD8 SK1 PerCP-eFluor 710 46-0087-42 Thermofisher
3 CD19 HIB19 eFluor 506 69-0199-42 Thermofisher
4 CD38 HIT2 PE-eFluor 610 61-0389-42 Thermofisher
5 HLA-DR L243 Alexa Fluor 647 A51010 Thermofisher
6 GZMA (IC) CB9 PE 12-9177-42 Thermofisher
7 GZMB (IC) GB11 Alexa Fluor 488 MA5-23639 Thermofisher
8 Perforin (IC) dG9 PE-Cy7 12-9177-42 Thermofisher
Other Flow reagents
1 Ultracompensation bead 01-2222-42 Thermofisher
2 Live/Dead Fixable Near IR staining kit L10119 Thermofisher
2 FOXP3/TRN FACTOR STAIN BUFFER SET 00-5523-00 Thermofisher
3 FLOW STAIN BUFFER SOLN 00-4222-57 Thermofisher
4 SB COMPLETE STAINING BUFFER SB-4401-42 Thermofisher
5 DPBS D8537 Sigma
6 Pancoll human P04-601000 Pan Biotech
Y. Singh et al. Heliyon 7 (2021) e07147cases highlights the importance of the perforin gene variant A91V which
results in the rapid demise in young COVID-19 patients [64]. The
possible implication of our finding is that convalescent patients, specif-
ically including cancer patients under treatment, could be susceptible to
future opportunistic infections with other viruses including different
variants of SARS-CoV-2. However, further, a large cohort study is war-
ranted to understand the potential functions of these molecules (gran-
zyme or perforin) in protection or susceptibility against the COVID-19
infection at gene and function levels.
To date, the general metabolic physiology of PBMCs is not well
defined in the literature. However, it is clear now that PBMCs are
dependent on circulating nutrients and hormones in the blood [65]. A
defective immune response in COVID-19 patients prompted us to inves-
tigate the metabolic functions of these immune cells. Our metabolomics
data indeed shows that PBMCs from actively infected patients have a
distinct metabolic profile from convalescent or healthy individuals. The
most notable difference we observed was for metabolites from the
glycolysis and oxidative phosphorylation (TCA cycle) pathway, which is13in accordance with recently published transcriptome data for PBMCs [39,
43]. Metabolites such as glucose, formate, acetate and choline were also
reduced in PBMCs in infected patients whereas, HC and convalescent
patients had a normal profile. Accordingly, the glycolytic pathway end
products such as lactate were higher in active mild and moderate
COVID-19 patients compared with HC and convalescent individuals.
Therefore, our data suggest that PBMCs (which constitute a major frac-
tion of T lymphoid cells: 70–80%) may have modulated their metabolic
functions, particularly favouring the oxidative phosphorylation pathway
over the glycolytic pathway, to meet the high demands of energy needed
to combat the ongoing viral infection.
A recent report suggested that elevated glucose levels enhance SARS-
CoV-2 replication and cytokine expression in monocytes and glycolysis
sustains the viral-induced monocyte response [66]. Recently, it was
emphasized that glucose consumption in PBMCs during COVID-19 dis-
ease could be also a read-out of cytokine storms [34]. Further, a higher
abundance of citrate in PBMCs suggested that perhaps T cells could use
the oxidative phosphorylation pathway for energy consumption to
Figure 10. Pattern hunter plots provide an insight of close correlations with other metabolites during COVID-19 infection. a. Variable Importance in Projection (VIP)
scores for all metabolites in the four studied groups. b. Pattern hunter plot for glucose. c. Pattern hunter plot for lactate. d. Pattern hunter plot for fructose.
Y. Singh et al. Heliyon 7 (2021) e07147endure the infection, as recent transcriptomic data also suggested that
higher expression of genes related to oxidative phosphorylation both in
peripheral mononuclear leukocytes and bronchoalveolar lavage fluid
(BALF) could play a crucial role in increased mitochondrial activity
during SARS-CoV-2 infection [34].
Another remarkable finding of our study was the increase of fructose
levels in PBMCs during the course of infection. Previous findings sug-
gested that fructose is involved in the inflammatory pathways for the
production of IL-1β and IL-6 production [67]. Thus, it is conceivable that
the immune cells (most probably monocytes) could be triggered by
higher fructose and simultaneously induce inflammation and IFN-γ pro-
duction by T cells [67]. These findings correlate with recent tran-
scriptomic studies on the BALF from infected COVID-19 patients and
plasma of COVID-19 patients that also identified changes in fructose
metabolism [34, 68].
Several amino acids are involved in anti-inflammatory effects,
especially arginine, glutamine and glycine appeared to improve lung
damage induced by infections [69]. Administration of glutamine
reduced the inflammatory cytokines, whereas arginine or glycine
reduced IL-6 and CXCL-1 expression in the alveolar epithelium [70].
Additionally, glutamine is an important signalling molecule involved
in activating mammalian target of rapamycin (mTOR) signalling
which is critical for immune cell activity and inhibiting catabolic
functions such as protein degradation and apoptosis [71]. In our study,
we found a reduced abundance of glutamate and glycine in PBMCs14during the mild and moderate COVID-19 patients. Reduced glucose
and glutamine are involved in the hexosamine biosynthetic pathway
and could be responsible for poor T cell clonal expansion and function
[41]. The exact molecular mechanism of individual amino acids is a
complex phenomenon and currently unclear. However, at least in
theory, supplementation of glutamine and glycine could be beneficial
for COVID-19 patients.
We finally observed a reduction of granzyme A and perforin levels in
CD8þ T cells and detected an ambient level of antioxidant amino acid
taurine in convalescent patients, which could be involved in the modu-
lation of cytotoxic functions of CD8þ T cells. Both granzyme A and per-
forin are involved in ROS production and taurine serves as ROS
scavenger [72, 73]. Thus, decreased granzyme A and perforin could be
implicated in reduced ROS production for the impaired effectiveness of
CD8þ T cells in either convalescent patients or COVID-19 patients. This
should be the case, as taurine levels are generally increased during active
infection in mild/moderate patients compared to healthy controls and
are not specifically decreasing due to granzyme A and perforin lacking
ROS activity in COVID-19 patients. However, this finding needs further
investigation to validate this hypothesis as it is unclear how ROS and
taurine act together to affect the cytotoxic functions of immune CD8þ T
cells. In summary, the metabolomics data generated in this study pro-
vides first and crucial insights into the complex metabolic changes of
PBMCs during SARS-CoV-2 infections, warranting further future in-depth
investigation.
Y. Singh et al. Heliyon 7 (2021) e071474. Conclusions
Using immunophenotyping and metabolomics approaches we detec-
ted significant changes in PBMC samples of mildly and moderately
affected COVID-19 as well as convalescent patients compared with
healthy controls. The reduced percentage of NK cells in both mild and
moderate patient groups corresponded with the clustering of PBMCs
metabolite levels in the principal component analysis distinct from the
cluster formed by healthy and convalescent individuals. The dramatically
changed metabolic activity and pathways, such as glycolysis and TCA
cycle, might not only lead to a vulnerability of COVID-19 patients to
subsequent infections but can also offer insights into how PBMCs could
be manipulated towards a better survival and personalized treatment of
moderate and severe COVID-19 patients.
5. Limitation of the study
The current study is performed from the samples obtained during the
first wave of infections and suffers from the limited number of patients
used in the study. The use of appropriate controls such as influenza viral
infection would have been useful for a more generalized conclusion.
Therefore, results obtained in future studies might differ from subsequent
waves of infections in new patient cohorts. Further, the novel SARS-CoV-
2 variants or vaccine candidates might promote alternative host immune
evasion strategies to infect the host, thus, eliciting a different immune
response. Nonetheless, this study certainly highlights the importance of
distinct cell types as well as the crucial function of cell metabolism during
SARS-CoV-2 viral infection and even after recovery.
6. Materials and methods
6.1. Ethics statement
The study protocols were approved by the University of Tübingen,
Germany Human Research Ethics Committee (TÜCOV: 256/2020BO2
(convalescent study), COMIHY: (225/2020AMG1) (outpatient study)-
COMIHY, EUDRA-CT: 2020-001512-26, ClinicalTrials.gov ID:
NCT04340544, and COV-HCQ: (190//2020AMG1) (inpatient study)-
COV-HCQ, EUDRA-CT: 2020-001224-33, ClinicalTrials.gov ID:
NCT04342221, 556/2018BO2) and all associated procedures were car-
ried out in accordance with approval guidelines. All participants pro-
vided written informed consent in accordance with the Declaration of
Helsinki.6.2. Study participants
SARS-CoV-2 positive patients were used for this study and no other
virus species were analysed in this study (COMIHY and COV-HCQ). Blood
was collected from COVID-19 patients enrolled into two different pro-
spective randomized, placebo-controlled, double-blind clinical trials
evaluating the safety and efficacy of hydroxychloroquine in COVID-19
outpatients (COMIHY) and hospitalized patients (COV-HCQ). We ana-
lysed subsets of these study cohort and used outpatient (n ¼ 3; COMIHY)
which came to a specified outpatient ward at the Institute of Tropical
Medicine with mild symptoms and blood was taken and usually defined
as D1 outpatients. Inpatients (n ¼ 3; COV-HCQ), blood was taken after
7–9 days after study inclusion defined as D7. These patients had mod-
erate symptoms needing hospital care, however not being transferred to
the intensive care unit in the hospital. Furthermore, convalescent COVID-
19 patients (n ¼ 4) were defined as positive for serum antibody reactive
to SARS-CoV-2 and blood was taken when they visited the Institute of
Tropical Medicine for testing of antibody levels. Amongst this cohort, 3
persons reported mild fever for 10–11 days and 1 individual reported no
fever but found positive for SARS-CoV-2 antibodies. Blood from healthy
controls (n ¼ 5) was obtained from the hospital blood bank.156.3. Flow cytometry and UMAP data analysis
PBMCs were isolated by the standard Ficoll method [74]. A total of
1–2 x106 PBMCs per participants were used for three FACS panels (Table
3). In brief, firstly, to distinguish between live from dead, the cells were
incubated with LIVE/DEAD Fixable Infra-Red Dead stain (Thermofisher)
for 15 min at room temperature (RT) into 1:40 diluted dye in DPBS.
Subsequently, after LIVE/DEAD staining, cells were stained with surface
markers in DPBS (Sigma) with Super Bright stain Buffer (Thermofisher)
for 30 min at RT. After surface staining cells were also stained for
intracellular (IC) markers. Before IC staining, cells were fixed for 30–45
min and permeabilized for 5 min followed by IC antibody incubation for
additional 30 min at RT. Cells were washed and resuspended in DPBS
containing 2%FBS. Fixing of cells was performed irrespective of whether
the panel was used for IC staining or not to prevent the possible
contamination during the acquisition of the samples. All the staining
procedures were performed in the dark to avoid the photo-bleaching of
dyes. For each sample, 200,000 cells were acquired using BD LSRFortessa
(core facility) equipped with 4 lasers (violet, blue and yellow-green and
Red). Data were analysed using Flow Jo (Tree Star) and fluorescence
minus one controls (FMO) were used for setting up the arbitrary gates for
the major cell markers. Furthermore, UMAP dimensional reduction
analysis was performed using UMAP plug-in [45] in Flowjo software
using default setting except for minimum distance (0.2 instead of 0.5)
and population (n ¼ 15) as advised by a plug-in. First, dead/debris was
removed by gating (FSC-A vs SSC-A; linear scale) then using FSC-A vs
FSC-W, we focussed on singlets. The singlets were again gated for live
and dead discrimination. An equal number of live cells from each sample
(HC, mild and moderate) were concatenated and exported as a single FCS
file. This FSC file was subjected to UMAP analysis, each cell population
was either monocytes or lymphocytes were again subject to subsequent
UMAP analysis for clustering of specific sub-populations. Based on gating
or antibodies-stained cells (data-driven) analysis was performed and
summarized in Figure 3.
6.4. 1H-NMR metabolomics
To obtain PBMCs metabolites, PBMCs were suspended in an opti-
mized solvent extraction mixture of 9:1 (methanol: chloroform) as
described elsewhere in detail [75] and extracted with a focused ultra-
sound system (Covaris E220, Woburn, USA). The extraction solutions
were evaporated to dryness for 4 h in a vacuum concentrator and after-
wards pellets resuspended with 45 μL in a 1 mM TSP containing
deuterated phosphate buffer. After centrifugation at 20,000 x g for 10
min to remove residual macromolecules, 40 μL of the clear supernatant
were transferred to 1.7 mm NMR tubes. Spectra were recorded on
ultrashielded 600 MHz spectrometer (Bruker AVANCE III HD, Karlsruhe,
Germany) with a triple resonance 1.7 mm room temperature probe.
Spectra used for analysis were acquired with a 2h 55min lasting CPMG
pulse program. Metabolite annotation and quantification were done with
ChenomX NMR Suite 8.3.
6.5. Statistical analysis
Bar diagrams were prepared using GraphPad Prism 6.0. Data shown
are means  SD. FACS data were analysed using one-way analysis of
variance (ANOVA) for multiple group comparisons (mild, moderate,
convalescent and HC) in GraphPad Prism software. No matching or
pairing was used. Assumed Gaussian distribution with equal standard
deviations (SDs) for experimental design. The mean of each group was
compared with the mean of every other group and Tukey's post-hoc tests
for multiple comparisons were employed. P-value considered signifi-
cantly less than 0.05 or equal. Metabolite concentrations from 1H-NMR
analysis were exported as comma-separated value spreadsheet file to
MetaboAnalyst 4.0 software, normalized with probabilistic quantile
normalization (PQN) and range scaled. Unsupervised principal
Y. Singh et al. Heliyon 7 (2021) e07147component analysis (PCA), a dimensionality-reduction method was used
for clustering of all metabolites (PC1 and PC2 only). Multiple groups
comparison was performed using one way ANOVA. Multivariate data
analysis techniques such as partial least squares analysis (PLS-DA) and
variable's importance in the PLS-DA (VIP) score analysis were used to
find the correlation among different metabolites and various groups.
Hierarchical clustering of all the metabolites was measured and distance
measurement was performed with Pearson r correlation coefficient.
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